Waltham, MA-based Dynogen and Apex Bioventures Acquisition (AMEX: [[ticker:PEX]]) have agreed to call off the $98 million reverse merger they originally announced in February. Citing market conditions, the firms said the terminating the merger agreement was in the best interests of both companies. Dynogen will seek alternative means of financing its programs, which include clinical-stage work on drugs for irritable bowel syndrome and nocturnal gastroesophageal reflux disease.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
